ATE154239T1 - Sphäroidische arzneimittelformulierung - Google Patents

Sphäroidische arzneimittelformulierung

Info

Publication number
ATE154239T1
ATE154239T1 AT93301140T AT93301140T ATE154239T1 AT E154239 T1 ATE154239 T1 AT E154239T1 AT 93301140 T AT93301140 T AT 93301140T AT 93301140 T AT93301140 T AT 93301140T AT E154239 T1 ATE154239 T1 AT E154239T1
Authority
AT
Austria
Prior art keywords
active ingredient
sugar
spherouidic
drug formulation
dissolution rate
Prior art date
Application number
AT93301140T
Other languages
English (en)
Inventor
Trevor John Knott
Stewart Thomas Leslie
Sandra Therese Antoi Malkowska
Ronald Brown Dr Miller
Philip John Neale
Derek Allan Prater
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of ATE154239T1 publication Critical patent/ATE154239T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT93301140T 1992-02-20 1993-02-17 Sphäroidische arzneimittelformulierung ATE154239T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929203689A GB9203689D0 (en) 1992-02-20 1992-02-20 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
ATE154239T1 true ATE154239T1 (de) 1997-06-15

Family

ID=10710782

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93301140T ATE154239T1 (de) 1992-02-20 1993-02-17 Sphäroidische arzneimittelformulierung

Country Status (6)

Country Link
US (1) US5622722A (de)
EP (1) EP0557065B1 (de)
JP (1) JP3667778B2 (de)
AT (1) ATE154239T1 (de)
DE (1) DE69311395T2 (de)
GB (2) GB9203689D0 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0613358Y2 (ja) * 1986-03-26 1994-04-06 吉田工業株式会社 自動扉
JPS6443686A (en) * 1987-08-07 1989-02-15 Yoshida Kogyo Kk Drive for automatic door
GB9310030D0 (en) * 1993-05-15 1993-06-30 Scras Dry processed particles and process for the preparation of the same
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DK1685839T3 (da) 1997-12-22 2013-06-24 Euro Celtique Sa Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
CN1204890C (zh) * 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
US7771746B2 (en) * 1999-12-03 2010-08-10 Polichem Sa Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
AU776666B2 (en) 2000-02-08 2004-09-16 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
KR100381623B1 (ko) * 2000-08-30 2003-04-26 디디에스텍주식회사 비우식성 구강적용 제제
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
US7943173B2 (en) * 2001-07-18 2011-05-17 Purdue Pharma L.P. Pharmaceutical combinations of oxycodone and naloxone
WO2003013525A1 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
CA2478515C (en) 2002-04-05 2010-09-28 Purdue Pharma Pharmaceutical preparation containing oxycodone and naloxone
DK1551372T3 (en) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
EP1604666A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
US7537240B2 (en) * 2005-02-22 2009-05-26 Automotive Systems Laboratory, Inc. Gas generating system
EP1702558A1 (de) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
DE112006001781T5 (de) * 2005-06-30 2008-05-08 Automotive Systems Laboratory, Inc., Armada Gaserzeuger
EP2010162A4 (de) * 2006-04-03 2013-01-09 Isa Odidi Zusammensetzung zur abgabe eines arzneimittels
KR101486228B1 (ko) * 2006-06-19 2015-01-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
US20080075768A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophobic opioid abuse deterrent delivery system using opioid antagonists
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
KR20130105935A (ko) * 2008-07-07 2013-09-26 유로-셀티큐 에스.에이. 요폐의 치료를 위한 아편유사제 길항제의 용도
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10702485B2 (en) * 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
KR20180037074A (ko) 2013-07-23 2018-04-10 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
US10487199B2 (en) 2014-06-26 2019-11-26 The Procter & Gamble Company Activated films having low sound pressure levels
US10842687B2 (en) 2014-08-27 2020-11-24 The Procter & Gamble Company Pant structure with efficiently manufactured and aesthetically pleasing rear leg edge profile
EP3236906B1 (de) 2014-12-25 2020-01-22 The Procter and Gamble Company Saugfähiger artikel mit elastischem band
JP7225834B2 (ja) 2019-01-24 2023-02-21 セイコーエプソン株式会社 粗砕装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795766A (fr) * 1972-02-22 1973-08-22 Lilly Co Eli Particules de napsylate de propoxyphene retard et procede de fabrication de ces particules
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
GB8525348D0 (en) * 1985-10-15 1985-11-20 Nicholas Kiwi Pacific Pty Ltd Effervescent tablets
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5049394A (en) * 1987-09-11 1991-09-17 E. R. Squibb & Sons, Inc. Pharmaceutical composition containing high drug load and method for preparing same
US4867785A (en) * 1988-05-09 1989-09-19 Ovonic Synthetic Materials Company, Inc. Method of forming alloy particulates having controlled submicron crystallite size distributions
EP0418597A3 (en) * 1989-09-21 1991-11-27 American Cyanamid Company Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form
EP0452862B1 (de) * 1990-04-18 1995-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Kugelförmige Keimkerne, kugelförmige Granulate sowie Verfahren zu deren Herstellung
GB2258810B (en) * 1991-08-12 1996-01-31 Euro Celtique Sa Pharmaceutical combination formulation of diltiazem and hydrochlorothiazide
US5350584A (en) * 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins

Also Published As

Publication number Publication date
GB2264640A (en) 1993-09-08
EP0557065A1 (de) 1993-08-25
EP0557065B1 (de) 1997-06-11
US5622722A (en) 1997-04-22
GB9303133D0 (en) 1993-03-31
DE69311395D1 (de) 1997-07-17
JPH0616552A (ja) 1994-01-25
GB9203689D0 (en) 1992-04-08
GB2264640B (en) 1996-05-22
JP3667778B2 (ja) 2005-07-06
DE69311395T2 (de) 1997-10-30

Similar Documents

Publication Publication Date Title
DE69311395D1 (de) Sphäroidische Arzneimittelformulierung
ATE167629T1 (de) Arzneimittel mit verzögerter freigabe
NO912001L (no) Buccal tablett med hurtig utlevering.
NO20022014L (no) En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon
DE3773468D1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
IE871981L (en) Programmed release formulation.
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
ATE202926T1 (de) Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung
WO2001043749A3 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
TW234691B (de)
NO306894B1 (no) Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
IE64850B1 (en) Therapeutically active substituted benzimidazole and process for its preparation
EP1219624A4 (de) Heilmittel für neuropathischen schmerz und versuchstier-modelle des neuropathischen schmerzes
CA2032475A1 (en) Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
GR890100833A (en) Process for the preparation of a compound with gastric inhibitopy effect
ATE374600T1 (de) Pharmazeutische formulierung enthaltend olanzapin
CA2120001A1 (en) Flavopereirine-based pharmaceutical composition and use thereof for treating hiv
ATE204474T1 (de) Amethocain enthaltende arzneimittel
DE69311394D1 (de) Arzneimittel verzögerter Wirkstoffabgabe
FR2469407A1 (fr) Nouveau derive de la quinazolinone, sa preparation et son application comme medicament
KR927003530A (ko) 이온삼투요법용 제약 제제의 제조에 있어서의 국소 마취제의 용도
CA2187153A1 (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties